Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Blood cancer journal [Blood Cancer J] NLMUID: 101568469"" wg kryterium: JN


Tytuł:
In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancies.
Autorzy:
Song Z; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 200433, Shanghai, China.
Liu P; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 200433, Shanghai, China.
Zhang D; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 200433, Shanghai, China.
Wang T; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 200433, Shanghai, China.
Yue W; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 200433, Shanghai, China.
Geng Y; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 200433, Shanghai, China.
Liu N; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 200433, Shanghai, China. .
Wang Y; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 200433, Shanghai, China. .
Yang J; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 200433, Shanghai, China. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Mar 15; Vol. 14 (1), pp. 46. Date of Electronic Publication: 2024 Mar 15.
Typ publikacji:
Letter
Opinia redakcyjna
Tytuł:
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation.
Autorzy:
Penack O; Medical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin, Germany. .; EBMT Transplant Complications Working Party, Paris, France. .
Abouqateb M; EBMT Transplant Complications Working Party, Paris, France.; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR-S 938, Sorbonne University, Paris, France.
Peczynski C; EBMT Transplant Complications Working Party, Paris, France.; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR-S 938, Sorbonne University, Paris, France.
Boreland W; EBMT Transplant Complications Working Party, Paris, France.; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR-S 938, Sorbonne University, Paris, France.
Gülbas Z; Anadolu Medical Center Hospital, Kocaeli, Turkey.
Gedde-Dahl T; Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Castilla-Llorente C; Gustave Roussy Cancer Campus, Villejuif, France.
Kröger N; University Medical Center, Department for Stem Cell Transplantation, Hamburg, Germany.
Eder M; Hannover Medical School, Hannover, Germany.
Rambaldi A; ASST Papa Giovanni XXIII, Bergamo, Italy.
Bonifazi F; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Blau IW; Medical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Stelljes M; University of Muenster, Muenster, Germany.
Dreger P; University of Heidelberg, Heidelberg, Germany.
Moiseev I; RM Gorbacheva Research Institute, Pavlov University, St Petersburg, Russia.
Schoemans H; EBMT Transplant Complications Working Party, Paris, France.; Department of Hematology, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
Koenecke C; EBMT Transplant Complications Working Party, Paris, France.; Hannover Medical School, Hannover, Germany.
Peric Z; EBMT Transplant Complications Working Party, Paris, France.; Department of Haematology, University Hospital Centre Rijeka, Rijeka, Croatia.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Mar 15; Vol. 14 (1), pp. 45. Date of Electronic Publication: 2024 Mar 15.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century.
Autorzy:
Hemminki K; Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, 30605, Pilsen, Czech Republic. .; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany. .
Zitricky F; Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, 30605, Pilsen, Czech Republic.
Försti A; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
Kontro M; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.; Foundation for the Finnish Cancer Institute, Helsinki, Finland.; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Gjertsen BT; Centre for Cancer Biomarkers (CCBIO), Department of Clinical Science, University of Bergen, Bergen, Norway.; Hematology Section, Department of Medicine, Haukeland University Hospital, Helse Bergen HF, Bergen, Norway.
Severinsen MT; Department of Hematology, Clinical Cancer Research Unit, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Juliusson G; Department of Hematology, Skåne University Hospital, Lund, Sweden.; Department of HematologyStem Cell Center, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Mar 14; Vol. 14 (1), pp. 44. Date of Electronic Publication: 2024 Mar 14.
Typ publikacji:
Letter
MeSH Terms:
Leukemia, Myeloid, Acute*/epidemiology
Leukemia, Myeloid, Acute*/therapy
Humans ; Scandinavian and Nordic Countries/epidemiology ; Age Factors
Opinia redakcyjna
Tytuł:
Large differencies in age-specific survival in multiple myeloma in the nordic countries.
Autorzy:
Hemminki K; Biomedical Center, Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, 30605, Pilsen, Czech Republic. .; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany. .
Zitricky F; Biomedical Center, Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, 30605, Pilsen, Czech Republic.
Försti A; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
Silvennoinen R; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, & University of Helsinki, Helsinki, Finland.
Vangsted A; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Hansson M; Department of Internal Medicine and Clinical Nutrition, Sahlgrenska University Hospital/Sahlgrenska Academy, Bruna stråket 5 plan 5, 41325, Göteborg, Sweden.; Hematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, 221 84, Lund, Sweden.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Mar 11; Vol. 14 (1), pp. 43. Date of Electronic Publication: 2024 Mar 11.
Typ publikacji:
Letter
MeSH Terms:
Multiple Myeloma*/epidemiology
Multiple Myeloma*/therapy
Humans ; Scandinavian and Nordic Countries/epidemiology ; Risk Factors ; Age Factors
Opinia redakcyjna
Tytuł:
Regulation of HOX gene expression in AML.
Autorzy:
Khan I; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.; Department of Medicine at the Feinberg School of Medicine, Northwestern University, Chicago, USA.
Amin MA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Eklund EA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.; Department of Medicine at the Feinberg School of Medicine, Northwestern University, Chicago, USA.; Jesse Brown VA Medical Center, Chicago, IL, USA.
Gartel AL; Department of Medicine, University of Illinois, Chicago, IL, USA. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Mar 07; Vol. 14 (1), pp. 42. Date of Electronic Publication: 2024 Mar 07.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Homeodomain Proteins*/genetics
Homeodomain Proteins*/metabolism
Leukemia, Myeloid, Acute*/pathology
Humans ; Nuclear Proteins/genetics ; Nucleophosmin ; Gene Expression Regulation, Leukemic ; Transcription Factors/genetics ; Chromatin ; Gene Expression
Czasopismo naukowe
Tytuł:
Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma.
Autorzy:
Keijzer K; Department of Hematology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
de Boer JW; Department of Hematology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
van Doesum JA; Department of Hematology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
Noordzij W; Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
Huls GA; Department of Hematology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
van Dijk LV; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
van Meerten T; Department of Hematology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
Niezink AGH; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Mar 07; Vol. 14 (1), pp. 41. Date of Electronic Publication: 2024 Mar 07.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma, Large B-Cell, Diffuse*/therapy
Humans ; Tumor Burden ; Adaptor Proteins, Signal Transducing ; Antigens, CD19 ; T-Lymphocytes
Czasopismo naukowe
Tytuł:
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Autorzy:
Rodriguez-Otero P; Clínica Universidad de Navarra, CCUN, University of Navarra, Pamplona, Spain. .
van de Donk NWCJ; Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Pillarisetti K; Janssen Research & Development, Spring House, PA, USA.
Cornax I; Janssen Research & Development, La Jolla, CA, USA.
Vishwamitra D; Janssen Research & Development, Spring House, PA, USA.
Gray K; Janssen Scientific Affairs, Horsham, PA, USA.
Hilder B; Janssen Research & Development, Spring House, PA, USA.
Tolbert J; Janssen Research & Development, Spring House, PA, USA.
Renaud T; Janssen Research & Development, Raritan, NJ, USA.
Masterson T; Janssen Research & Development, Spring House, PA, USA.
Heuck C; Janssen Research & Development, Spring House, PA, USA.
Kane C; Janssen Research & Development, Spring House, PA, USA.
Verona R; Janssen Research & Development, Spring House, PA, USA.
Moreau P; University Hospital Hôtel-Dieu, Nantes, France.
Bahlis N; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.
Chari A; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Mar 06; Vol. 14 (1), pp. 40. Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:
Published Erratum
Tytuł:
Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy.
Autorzy:
Liu Y; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China.
Tu Y; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China.
Xiao J; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China.
Shen Y; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China.
Zhou B; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China.
Yang Q; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China.
Yu L; Shanghai Unicar Therapy Bio-Medicine Technology Co. Ltd, Shanghai, China.
Qi L; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China.
Chen J; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China.
Liu T; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China. .; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China. .
Wu D; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China. .; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China. .
Xu Y; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China. .; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Mar 06; Vol. 14 (1), pp. 39. Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:
Letter
MeSH Terms:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/therapy
Leukemia, Myeloid*
Humans ; Immunotherapy, Adoptive ; Chronic Disease
Opinia redakcyjna
Tytuł:
Unrelated donor hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for adults with severe aplastic anemia.
Autorzy:
Wu L; Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China.
Liu L; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, Jiangsu, China.
Zhao X; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Anemia Therapeutic Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Zhou M; Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China.
Fu A; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Zhang Y; Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China.
Yang W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Anemia Therapeutic Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Chen X; Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China.
Mo W; Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China.
Wang C; Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China.
Li Y; Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China.
Xu S; Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China.
Pan S; Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China.
Zhou R; Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China.
Meng F; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. .
Zhang F; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Anemia Therapeutic Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. .
Wu D; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, Jiangsu, China. .
Wang S; Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Mar 06; Vol. 14 (1), pp. 37. Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:
Letter
MeSH Terms:
Anemia, Aplastic*/therapy
Benzoates*
Hydrazines*
Pyrazoles*
Adult ; Humans ; Unrelated Donors
Opinia redakcyjna
Tytuł:
Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing.
Autorzy:
Li JR; Department of Medicine, Baylor College of Medicine, Houston, TX, USA.; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
Arsang-Jang S; Division of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Cheng Y; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Sun F; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
D'Souza A; Division of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Dhakal B; Division of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Hari P; Division of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Huang Q; Department of Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA.
Auer P; Division of Biostatistics, Institute for Health & Equity, and Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
Li Y; Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Urrutia R; Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Zhan F; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Shaughnessy JD Jr; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Janz S; Division of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Dong J; Division of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. .; Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. .; Medical College of Wisconsin Cancer Center, Milwaukee, WI, USA. .
Cheng C; Department of Medicine, Baylor College of Medicine, Houston, TX, USA. .; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA. .; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Mar 06; Vol. 14 (1), pp. 38. Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/genetics
Paraproteinemias*
Humans ; Plasma Cells ; Prognosis ; Sequence Analysis, RNA ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
Autorzy:
Mohan M; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Monge J; Division of Hematology/Oncology, Weill Cornell Medicine, New York, NY, USA.
Shah N; Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA.
Luan D; Division of Hematology/Oncology, Weill Cornell Medicine, New York, NY, USA.
Forsberg M; Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA.
Bhatlapenumarthi V; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Balev M; Multiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
Patwari A; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Cheruvalath H; Medical College of Wisconsin Medical School, Milwaukee, WI, USA.
Bhutani D; Multiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
Thanendrarajan S; Myeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Dhakal B; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Zangari M; Myeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Al-Hadidi S; Myeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Cooper D; Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA.
Lentzsch S; Multiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
van Rhee F; Division of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA.
D'Souza A; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Szabo A; Division of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA.
Schinke C; Myeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Chakraborty R; Multiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Mar 05; Vol. 14 (1), pp. 35. Date of Electronic Publication: 2024 Mar 05.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Multiple Myeloma*/drug therapy
Neoplasms, Plasma Cell*
Antibodies, Bispecific*
Antineoplastic Agents*
Pentaerythritol Tetranitrate*
Humans ; B-Cell Maturation Antigen ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study.
Autorzy:
Gong Z; Division of Hematology Oncology, Houston Methodist Hospital, Houston, TX, USA.
Umoru G; Division of Hematology Oncology, Houston Methodist Hospital, Houston, TX, USA.
Monge J; Division of Hematology/Oncology, Weill Cornell Medicine, New York, NY, USA.
Shah N; Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA.
Mohyuddin GR; Division of Hematology/Oncology, University of Utah, Salt Lake City, UT, USA.
Radhakrishnan SV; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Chakraborty R; Multiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
Rasche L; Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Schinke C; Myeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
D'Souza A; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Mohan M; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Mar 05; Vol. 14 (1), pp. 36. Date of Electronic Publication: 2024 Mar 05.
Typ publikacji:
Letter
MeSH Terms:
B-Cell Maturation Antigen*
Multiple Myeloma*/therapy
Humans ; T-Lymphocytes
Opinia redakcyjna
Tytuł:
Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.
Autorzy:
Horna P; Division of Hematopathology, Mayo Clinic, Rochester, MN, USA. .
Weybright MJ; Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.
Ferrari M; Autolus Ltd, London, UK.
Jungherz D; Department of Internal Medicine, University of Cologne, Cologne, Germany.
Peng Y; Department of Internal Medicine, University of Cologne, Cologne, Germany.
Akbar Z; Autolus Ltd, London, UK.
Tudor Ilca F; Autolus Ltd, London, UK.
Otteson GE; Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.
Seheult JN; Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.
Ortmann J; Centre de Recherches Mathematiques, Universite du Quebec a Montreal, Montreal, Canada.
Shi M; Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.
Maciocia PM; Cancer Institute, University College London, London, UK.
Herling M; Department of Internal Medicine, University of Cologne, Cologne, Germany.
Pule MA; Autolus Ltd, London, UK.; Cancer Institute, University College London, London, UK.
Olteanu H; Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Feb 29; Vol. 14 (1), pp. 34. Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:
Journal Article
MeSH Terms:
CD8-Positive T-Lymphocytes*
Lymphoma*
Humans ; Flow Cytometry/methods ; B-Lymphocytes/pathology ; Staining and Labeling
Czasopismo naukowe
Tytuł:
Update on the management of relapsed/refractory chronic lymphocytic leukemia.
Autorzy:
Bennett R; Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, 305 Grattan St, Parkville, Melbourne, VIC, 3000, Australia.
Seymour JF; Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, 305 Grattan St, Parkville, Melbourne, VIC, 3000, Australia. .; University of Melbourne, Grattan St, Parkville, Melbourne, VIC, 3010, Australia. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Feb 21; Vol. 14 (1), pp. 33. Date of Electronic Publication: 2024 Feb 21.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/etiology
Lymphoma, B-Cell*/drug therapy
Antineoplastic Agents*/therapeutic use
Humans ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Agammaglobulinaemia Tyrosine Kinase ; Antibodies, Monoclonal/therapeutic use
Czasopismo naukowe
Tytuł:
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Autorzy:
Badar T; Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA. .
Nanaa A; Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.; Division of Hematology, Mayo Clinic, Rochester, MN, USA.; Department of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA.
Atallah E; Division of Hematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Shallis RM; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Guilherme SCC; Department of Internal Medicine, Mount Sinai Health System, New York, USA.
Goldberg AD; Division of Hematologic Malignancies, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Saliba AN; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Patel A; Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
Bewersdorf JP; Division of Hematologic Malignancies, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, NY, USA.
DuVall AS; Division of Hematology and Oncology, Georgia Cancer Center, Augusta, GA, USA.
Bradshaw D; Division of Hematology and Oncology, Georgia Cancer Center, Augusta, GA, USA.
Abaza Y; Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago, IL, USA.
Murthy GSG; Division of Hematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Palmisiano N; Division of Hematology and Oncology, Jefferson University Hospital, Philadelphia, PA, USA.
Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Kota V; Division of Hematology and Oncology, Georgia Cancer Center, Augusta, GA, USA.
Litzow MR; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Feb 20; Vol. 14 (1), pp. 32. Date of Electronic Publication: 2024 Feb 20.
Typ publikacji:
Comparative Study; Letter; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/pathology
Humans ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Sulfonamides/pharmacology ; Sulfonamides/therapeutic use ; Tumor Suppressor Protein p53/genetics
Raport
Tytuł:
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Autorzy:
Brissot E; Sorbonne Université, AP-HP, INSERM UMRs938, Paris, France ; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France. .
Labopin M; Sorbonne Université, AP-HP, INSERM UMRs938, Paris, France ; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.; European Society for Blood and Marrow Transplantation Paris Study Office/CEREST-TC, Paris, France.
Labussière H; Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France.
Fossard G; Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France.
Chevallier P; Hematology Department, Center Hospitalier Universitaire de Nantes, Nantes, France.
Guillaume T; Hematology Department, Center Hospitalier Universitaire de Nantes, Nantes, France.
Yakoub-Agha I; CHU Lille, Department of Hematology, Univ. Lille, INSERM U1286, Infinite, F-59000, Lille, France.
Srour M; CHU Lille, Department of Hematology, Univ. Lille, INSERM U1286, Infinite, F-59000, Lille, France.
Bulabois CE; Department of Hematology, CHU de Grenoble, Grenoble, France.
Huynh A; CHU-Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O), Toulouse, France.
Chantepie S; Service d'Hématologie, Institut d'Hématologie de Basse-Normandie CHU de Caen, Caen, France.
Menard AL; Department of Hematology, Center Henri Becquerel, Rouen, France.
Rubio MT; University Hospital of Nancy, Vandoeuvre-Les-Nancy, France.
Ceballos P; Hematology Department, Saint-Eloi University Hospital, Montpellier, France.
Dulery R; Sorbonne Université, AP-HP, INSERM UMRs938, Paris, France ; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
Furst S; Transplant and cellular immunotherapy program, Department of hematology, Institut Paoli Calmettes, Cancer research center of Marseille (CRCM), Aix-Marseille University (AMU), Marseille, France.
Malard F; Sorbonne Université, AP-HP, INSERM UMRs938, Paris, France ; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
Blaise D; Transplant and cellular immunotherapy program, Department of hematology, Institut Paoli Calmettes, Cancer research center of Marseille (CRCM), Aix-Marseille University (AMU), Marseille, France.
Mohty M; Sorbonne Université, AP-HP, INSERM UMRs938, Paris, France ; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Feb 19; Vol. 14 (1), pp. 31. Date of Electronic Publication: 2024 Feb 19.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Humans ; Antilymphocyte Serum/therapeutic use ; Unrelated Donors ; Siblings ; Quality of Life ; Cyclophosphamide/therapeutic use ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
Autorzy:
Guo W; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.; Department of Haematology, Second Xiang-ya Hospital, Central South University, Changsha, Hunan, China.
Zhan Y; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.; Department of Haematology, Second Xiang-ya Hospital, Central South University, Changsha, Hunan, China.
Mery D; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Siegel ER; Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Sun F; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Cheng Y; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Ashby TC; Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Zhang Z; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Bailey C; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Alapat DV; Department of Pathology Clinical, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Peng H; Department of Haematology, Second Xiang-ya Hospital, Central South University, Changsha, Hunan, China.
Hadidi SA; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Thanendrarajan S; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Schinke C; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Zangari M; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
van Rhee F; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Tricot G; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Shaughnessy JD; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. .
Zhan F; Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Feb 14; Vol. 14 (1), pp. 30. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:
Letter; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Multiple Myeloma*
Hematopoietic Stem Cell Transplantation*
Humans ; Prognosis ; Ferritins ; Retrospective Studies ; Transplantation, Autologous
Raport
Tytuł:
Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma.
Autorzy:
Xu D; Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Sq, London, UK. .; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Sq, London, UK. .; Centre for Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK. .; Oxford Cancer and Haematology centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK. .
Bewicke-Copley F; Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Sq, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Sq, London, UK.
Close K; Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Sq, London, UK.
Okosun J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Sq, London, UK.
Gale RP; Centre for Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
Apperley J; Centre for Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Merck and Co., Rahway, NJ, USA.
Wendel HG; Memorial Sloan-Kettering Cancer Center, Cancer Biology & Genetics, New York, NY, 10065, USA.
Fitzgibbon J; Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Sq, London, UK.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Feb 13; Vol. 14 (1), pp. 29. Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Lysine*
Lymphoma, Mantle-Cell*/drug therapy
Humans ; Adult ; Histone Demethylases
Raport
Tytuł:
Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.
Autorzy:
Larsen MK; Department of Hematology, Zealand University Hospital, Roskilde, Denmark. .; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. .
Skov V; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Kjær L; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Eickhardt-Dalbøge CS; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Knudsen TA; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Kristiansen MH; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Neurology, Zealand University Hospital, Roskilde, Denmark.
Sørensen AL; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Wienecke T; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Neurology, Zealand University Hospital, Roskilde, Denmark.
Andersen M; Department of Science and Environment, Roskilde University, Roskilde, Denmark.
Ottesen JT; Department of Science and Environment, Roskilde University, Roskilde, Denmark.
Gudmand-Høyer J; Department of Science and Environment, Roskilde University, Roskilde, Denmark.
Snyder JA; Department of Science and Environment, Roskilde University, Roskilde, Denmark.
Andersen MP; Department of Cardiology, Copenhagen University Hospital, Nordsjællands Hospital, Hillerød, Denmark.
Torp-Pedersen C; Department of Cardiology, Copenhagen University Hospital, Nordsjællands Hospital, Hillerød, Denmark.
Poulsen HE; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Cardiology, Copenhagen University Hospital, Nordsjællands Hospital, Hillerød, Denmark.; Department of Endocrinology, Copenhagen University Hospital, Bispebjerg Frederiksberg Hospital, Copenhagen, Denmark.
Stiehl T; Department of Science and Environment, Roskilde University, Roskilde, Denmark.; Institute for Computational Biomedicine - Disease Modelling, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Hasselbalch HC; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Ellervik C; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Biochemistry, Zealand University Hospital, Koege, Denmark.; Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Feb 09; Vol. 14 (1), pp. 28. Date of Electronic Publication: 2024 Feb 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Myeloproliferative Disorders*/epidemiology
Polycythemia Vera*
Primary Myelofibrosis*/epidemiology
Thrombocythemia, Essential*/epidemiology
Humans ; Longitudinal Studies ; Neutrophils ; Lymphocytes ; Denmark/epidemiology
Czasopismo naukowe
Tytuł:
Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
Autorzy:
Trabolsi A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Fl, USA.; Hematology-Oncology Fellowship Program, Jackson Memorial Health System/ University of Miami, Miami, Fl, USA.
Arumov A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Fl, USA.; Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Fl, USA.
Schatz JH; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Fl, USA. .; Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Fl, USA. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Feb 08; Vol. 14 (1), pp. 27. Date of Electronic Publication: 2024 Feb 08.
Typ publikacji:
Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Bispecific*/therapeutic use
Lymphoma, Large B-Cell, Diffuse*/pathology
Humans ; Neoplasm Recurrence, Local/etiology ; Immunotherapy ; T-Lymphocytes ; Immunotherapy, Adoptive/adverse effects
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies